Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study

Clinical and Experimental Rheumatology

Volumn 19, Issue 5, 2001, Pages 503-508

  Scorza, R ^a   Caronni, M ^a   Mascagni, B ^a   Berruti, V ^a   Bazzi, S ^a   Micallef, E ^a   Arpaia, G ^a   Sardina, M ^a   Origgi, L ^a   Vanoli, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Controlled clinical trial; Iloprost; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ADALAT AR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PENICILLAMINE; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERKINESIA; HYPOTENSION; JAW DISEASE; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MYALGIA; NAUSEA AND VOMITING; PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SCORING SYSTEM; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS; TACHYCARDIA; VASOSPASM;

ADULT; AGED; FEMALE; HUMANS; ILOPROST; MALE; MIDDLE AGED; NIFEDIPINE; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SINGLE-BLIND METHOD; SKIN; SKINFOLD THICKNESS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0034837756     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Clinical aspects of systemic sclerosis (scleroderma)
2. The endothelium in the pathogenesis of systemic sclerosis: Is it primary or secondary?
3. Biology of the scleroderma fibroblast
4. Dissociation of platelet aggregation and vasodilatation with iloprost: A stable orally active, prostacyclin derivative
5. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes
6. Cytokine production in sclerodermia patients: Effects of therapy with either iloprost or nifedipine
7. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomized study
8. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon
9. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis
10. A double blind, randomised, multicentre, comparison of two doses of intravenous iloprost in the treatment of Rynaud's phenomenon secondary to connective tissue diseases
11. Double-blind comparison of three days infusion of iloprost and continuous oral nifedipine on symptomatology and digital blood flow in patients with Raynaud's phenomenon secondary to systemic sclerosis
12. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue
13. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis
14. Microcirculatory effects of Iloprost in patients with suspected secondary Raynaud phenomenon
15. Effect of Iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis
16. Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy
17. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases
18. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
19. La velocimetria doppler nella diagnostica arteriosa dell'arto superiore
20. Reliability of skin involvement measures in scleroderma
21. Standardized lung function testing: Report from working party on "standardisation of lung function test", European Community for Coal and Steel
22. Epidemiology and natural history of systemic sclerosis
23. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions
24. Plicometer skin test: A new technique for the evaluation of cutaneous involvement in systemic sclerosis
25. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis
26. Diffusing capacity of the lung and nifedipine in systemic sclerosis
27. Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis
28. Regulation of the immune response by prostaglandins
29. Immunomodulation by eicosanoids and anti-inflammatory drugs